[PDF][PDF] Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study
M Untch, M Rezai, S Loibl, PA Fasching… - Journal of Clinical …, 2010 - researchgate.net
M Untch, M Rezai, S Loibl, PA Fasching, J Huober, H Tesch, I Bauerfeind, J Hilfrich…
Journal of Clinical Oncology, 2010•researchgate.netPurpose Trastuzumab, a humanized antibody against the human epidermal growth factor
receptor type 2 (HER2), has shown high efficacy in breast cancer. We prospectively
investigated its efficacy given simultaneously with anthracycline-taxane–based neoadjuvant
chemotherapy.
receptor type 2 (HER2), has shown high efficacy in breast cancer. We prospectively
investigated its efficacy given simultaneously with anthracycline-taxane–based neoadjuvant
chemotherapy.
Purpose
Trastuzumab, a humanized antibody against the human epidermal growth factor receptor type 2 (HER2), has shown high efficacy in breast cancer. We prospectively investigated its efficacy given simultaneously with anthracycline-taxane–based neoadjuvant chemotherapy.
researchgate.net
